Free Newsletter
Wyeth execs slated for $22M payouts
These days, reading SEC documents is like being a fly on the wall in pharma's board rooms. Today, reporters observe that top Wyeth managers will reap a total of $22 million in payouts from the company when it's taken over by Pfizer later this year.
The biggest check will go to CEO Bernard Poussot (photo), in the amount of $10.25 million, the Associated Press reports. Gregory Nordon, CFO, is slated to receive a tad over $3 million, while Joseph Mahady, SVP and Wyeth Pharma chief, can plan on $3.62 million. Research chief Mikael Dolsten is down for $3 million. Bringing up the rear: general counsel Lawrence Stein and his $2.11 million payout.
The awards won't be fully vested until the Pfizer deal is complete, or until the manager either is dismissed "without cause" or resigns with a good excuse for leaving. They'll take the place of the usual stock and stock options awarded top execs each spring.
- see the AP story
Related Articles:
Top 17 paychecks in Big Pharma
Wyeth, Pfizer chiefs see pay decline
The best of paychecks, the worst of paychecks ...
Pfizer-Wyeth: 'great strategy' or 'extremely disruptive'?
How will Kindler mix Wy-Pfi? Very carefully
Pfizer to add Wyeth directors to board
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: